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Over the past decade, patients with advanced non-small-cell lung cancer (NSCLC) 
have witnessed substantial advances in regards to therapeutic alternatives. Among 
newly developed agents, angiogenesis inhibitors were extensively tested in different 
settings and have produced some favorable outcomes despite several shortcomings. 
Bevacizumab is the most examined agent in this context and has demonstrated signif-
icant survival benefits when combined with standard chemotherapy in eligible patients. 
Preliminary results on the addition of bevacizumab to erlotinib in patients with EGFR-
mutated NSCLC seem promising. Other antiangiogenic agents were also tested, but 
ramucirumab and nintedanib are the only agents with a positive impact on survival. More 
recently, immune checkpoint inhibitors (ICIs) have had considerable success due to their 
prolonged durations of response, yet response rates are still deemed suboptimal, and 
various combination therapies are being tested in an effort to improve efficacy. Preclinical 
evidence suggests an immunosuppressive effect of pro-angiogenic factors, which sets 
up a plausible rationale for combining ICIs and antiangiogenic agents. Herein, we review 
the landmark data supporting the success of angiogenesis inhibitors, and we discuss 
the potential for combination with immunotherapy and targeted agents.
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inTRODUCTiOn
A decade has now passed since bevacizumab, the first promising antiangiogenic agent, was approved 
for the treatment of non-small-cell lung cancer (NSCLC), and the lessons learned revealed that 
clinical applications of antiangiogenesis are somewhat more challenging than initially believed (1). 
As a fully humanized monoclonal antibody (mAb) that binds vascular endothelial growth factor-A 
(VEGF-A) and prevents interaction with VEGFR-1 and VEGFR-2 (the primary receptors involved in 
endothelial cell proliferation and migration), bevacizumab was thought of as a “silver bullet” capable 
of targeting multiple types of cancer since tumor proliferation and spread depend on neo-vasculature 
(2–4). However, despite survival gains attributed to this agent, clinical trial results did not fully meet 
with the expectations and management of patients with advanced NSCLC still requires significant 
improvements in order to clearly affect outcomes in this first ranking cancer in terms of cancer-
related mortality (5). Nevertheless, angiogenesis remained an area of active research, and numerous 
agents have been tested. These agents bind VEGFR-2 directly (e.g., ramucirumab), act as VEGF 
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inhibitors (e.g., aflibercept), or block intracellular downstream 
signal transduction by the inhibition of the tyrosine kinases of 
VEGF receptors (e.g., sorafenib and nintedanib) (6–8).
In the era of immunotherapy and refined precision medicine, 
the value of antiangiogenic agents and their cost-efficiency could 
be put into question in the face of more successful biologic agents 
such as immune checkpoint inhibitors (ICIs) that demonstrated 
significant clinical activity both in the first- and second-line set-
ting with much promise attributed to the durable responses they 
achieve in responding patients (9). On the other hand, combining 
immunotherapy and angiogenesis inhibitors could prove to be 
a successful undertaking, which might improve the efficacy of 
both agents. Herein, we will provide a review of noteworthy data 
relating to successful antiangiogenic agents in NSCLC, be it in 
combination with chemotherapy or with newer agents.
TARGeTinG veGF
Bevacizumab
Combination with Cytotoxic Therapy
The initial randomized phase II study of this anti-VEGF-A mAb 
evaluated two different doses of bevacizumab (7.5 and 15 mg/kg) 
in addition to paclitaxel/carboplatin vs. chemotherapy alone, and 
the results demonstrated significant improvements in terms of 
response rate (RR) (31.5 vs. 18.8%) and median time to progres-
sion (7.4 vs. 4.2 months, p = 0.023) in favor of the arm with the 
highest dose of bevacizumab compared with the control arm 
(10). A noteworthy outcome of this trial was the identification 
of clinical features that were associated with high rates of life-
threatening hemoptysis. Therefore, centrally located tumors with 
proximity to major blood vessels, cavitation, and squamous cell 
histology became exclusion criteria in most of the subsequent 
studies. However, ensuing data from the phase 4 SAiL study 
and the ARIES Observational Cohort study called into question 
whether cavitation and centrally located tumors did affect the rate 
of severe hemoptysis (11). Consequently, expert opinion suggests 
that squamous histology and the presence of hemoptysis are the 
most important contraindications to bevacizumab (12).
Following the success of the phase II study, a large phase III 
trial with a similar design conducted by the Eastern Cooperative 
Oncology Group (ECOG)—ECOG 4599—confirmed the ben-
efits of bevacizumab (at a dose of 15 mg/kg), in the same setting, 
in terms of overall survival (OS) (12.3 vs. 10.3 months, p = 0.003), 
RR (35 vs. 15%, p < 0.001), and progression free survival (PFS) 
(6.2 vs. 4.5 months, p < 0.001) (13). In Europe, the AVAiL phase 
III trial also attempted to confirm the benefit of bevacizumab 
but in combination with the cisplatin/gemcitabine doublet and 
at two different dose levels (7.5 and 15  mg/kg) (14). Although 
the improvements in PFS were statistically significant for both 
dose levels of bevacizumab (6.5 vs. 6.1 months, p = 0.03 for the 
higher dose and 6.7 vs. 6.1, p = 0.003 for the lower dose), the study 
design did not allow for a direct comparison between both dose 
levels. Additionally, a subsequent survival analysis failed to dem-
onstrate any OS benefit (15). Considering the modest absolute 
value of PFS improvements and the absence of any OS benefit, 
some experts favor the addition of bevacizumab to a paclitaxel/
carboplatin regimen and support a theory that paclitaxel might 
be more susceptible to positive modulation by bevacizumab 
(16–18). The results of the BEYOND study are in line with 
this reasoning. This more recent phase III study, evaluating the 
addition of bevacizumab (15 mg/kg) to a carboplatin/paclitaxel 
backbone chemotherapy regimen in a Chinese cohort, dem-
onstrated significant improvements in PFS [9.2 vs. 6.5 months; 
hazard ratio (HR), 0.40; 95% CI, 0.29–0.54; p < 0.001] and OS 
(24.3 vs. 17.7 months; HR, 0.68; 95% CI, 0.50–0.93; p = 0.0154) 
(19). Of particular note, the very favorable outcomes in terms of 
PFS and OS in the control arm seem to reflect a better selection 
of patients along with improvements in supportive care measures. 
Additionally, subsequent lines of therapy have most definitely 
impacted survival results in both arms as the EGFR mutation 
rates were 27 and 26% and the subsequent use of EGFR-TKI was 
36 and 38% for the experimental and standard arms, respectively 
(Table 1) (19).
To date, the available data were compiled in two different 
meta-analyses of platinum doublets combined with bevacizumab 
and both concluded to significant PFS and RR benefit from the 
addition of bevacizumab to standard cytotoxic therapy (20, 21). 
However, only one of these studies demonstrated a 10% relative 
reduction in the risk of death with the addition of bevacizumab 
to chemotherapy (HR: 0.90, 95% CI, 0.81–0.99) (21).
Bevacizumab was also tested in the adjuvant setting at a dose 
of 15  mg/kg in combination with cisplatin and vinorelbine, 
docetaxel, gemcitabine, or pemetrexed (for non-squamous 
histology) per physician’s choice. The results of the E1505 
phase III study were released after an interim analysis showed 
futility 41 months of follow-up. Additionally, patients receiving 
bevacizumab-containing therapy had significantly higher rates 
of grade 3–5 toxicities, mostly in the form of hypertension (8 vs. 
30%), neutropenia (33 vs. 38%), and overall worst grade (67 vs. 
84%) (22).
Maintenance Therapy and Dosing
Besides the issue of optimal backbone chemotherapy, other piv-
otal questions involve the duration of therapy with bevacizumab 
and the optimal dose of this agent.
In the landmark ECOG 4599 study, bevacizumab was contin-
ued until progression or limiting toxicities, and a retrospective 
analysis demonstrated superior PFS and OS in patients where 
bevacizumab was continued (PFS: 4.4 vs. 2.8; HR: 0.64, and 
OS: 12.8 vs. 11.4; HR: 0.75) (13, 23). Since then, three impor-
tant studies have addressed this issue. The POINTBREAK trial 
did not demonstrate any OS advantage when pemetrexed/
carboplatin/bevacizumab (15 mg/kg) followed by bevacizumab/
pemetrexed maintenance was compared with paclitaxel/car-
boplatin/bevacizumab followed by bevacizumab maintenance, 
but PFS favored the pemetrexed containing regimen (6.0 vs. 
5.6 months; p = 0.012). The AVAPERL study comparing cisplatin/
pemetrexed/bevacizumab followed by either pemetrexed or pem-
etrexed/bevacizumab maintenance, in non-progressing patients, 
demonstrated a substantial PFS advantage in favor of the doublet 
maintenance (7.4 vs. 3.7 months; HR, 0.57; 95% CI, 0.44–0.75; 
p <  0.0001), but OS did not reach statistical significance. The 
PRONOUNCE study did not demonstrate a survival difference 
TABLe 1 | Results of landmark trials evaluating antiangiogenic agents in metastatic non-small-cell lung cancer.
Study/phase Chemotherapy number of 
patients (n)
ORR 
(%)
Median 
PFS 
(months)
HR (95% Ci); p Median OS 
(months)
HR (95% Ci); p
ECOG 4599/
phase III
Pac/Carbo 444 15 4.5 HR = 0.66 (0.57–0.77); 
p < 0.001
10.3 HR = 0.79 (0.67–0.92); 
p = 0.003Pac/Carbo/Bev 434 35 6.2 12.3
AVAiL/phase III Cis/Gem 345 21.6 6.1 –HR = 0.75 (0.64–0.87); 
p = 0.0003
–HR = 0.85 (0.73–1.00); 
p = 0.0456
13.1 –HR = 0.93 (0.78–1.11); 
p = 0.420
–HR = 1.03 (0.86–0.54); 
p < 0.01
Cis/Gem/Bev
–7.5 mg/kg –345 –37.8 –6.7 –13.6
–15 mg/kg –351 –34.6 –6.4 –13.4
BEYOND/phase III Pac/Carbo 138 26 6.5 HR = 0.40 (0.29–0.54); 
p < 0.01
17.7 HR = 0.68 (0.50–0.93); 
p = 0.0154Pac/Carbo/Bev 138 54 9.2 24.3
AVAPERL/phase III Cis/Pem/Bev 376 – – – – –
Pem/Bev maintenance 128 – 7.4 HR = 0.57 (0.44–0.75); 
p < 0.0001
17.1 HR = 0.87 (0.63–1.21); 
p = 0.29Bev maintenance 125 – 3.7 13.2
POINTBREAK/
phase III
Carbo/Pem/Bev → Bev/Pem 
maintenance
472 34 6 HR = 0.83 (0.71–0.96); 
p = 0.012
13.4 HR = 1.0 (0.86–1.16); 
p = 0.949
Carbo/Pac/Bev → Bev 
maintenance
467 33 5.6 12.6
PRONOUNCE/
phase III
Carbo/Pem → Pem 182 23.6 4.44 HR = 1.06 (0.84–1.35); 
p = 0.610
10.5 HR = 1.07 (0.83–1.36); 
p = 0.615 Carbo/Pac/Bev → Bev 179 27.4 5.49 11.7
JO25567/phase II Erlotinib 75 64 9.7 HR = 0.54 (0.36–0.79); 
p = 0.0015
– –
Erlotinib/Bev 77 69 16.0 –
BELIEF/phase II Erlotinib/Bev 109 – 13.6 – – –
All patients 60 70.3 15.4 –
T790M-mutated EGFR
REVELa/phase III Docetaxel 625 14 3.0 HR = 0.76 (0.68–0.86); 
p < 0.0001
9.1 HR = 0.86 (0.75–0.98); 
p = 0.023Docetaxel/ramucirumab 628 23 4.5 10.5
LUME-lung 1a/
phase III
Docetaxel 659 1.5 1.5 HR = 0.63 (0.48–0.83); 
p = 0.0008
9.1 HR = 0.94 (0.83–1.05); 
p = 0.2720Docetaxel/nintedanib 655 4.9 3.6 10.1
LUME-lung 2a/
phase III
Pem 360 8.3 3.6 HR = 0.83 (0.70–0.99); 
p = 0.0435
12.7 HR = 1.03 (0.85–1.21); 
p = 0.8940Pem/nintedanib 353 9.1 4.4 12.2
HR, hazard ratio; PFS, progression free survival; OS, overall survival; Pac, paclitaxel; Carbo, carboplatin; Bev, bevacizumab; Cis, cisplatin; Gem, gemcitabine; Pem, pemetrexed; 
ECOG, Eastern Cooperative Oncology Group.
aTrials in the second-line setting.
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when pemetrexed/carboplatin followed by pemetrexed mainte-
nance was compared with paclitaxel/carboplatin/bevacizumab 
(15  mg/kg) followed by bevacizumab maintenance (Table  1) 
(24–26). When all these trials are taken together, it remains 
unclear whether the demonstrated benefit of maintenance 
pemetrexed is improved by bevacizumab. An ongoing phase III 
study with three different maintenance therapies (ECOG 5508; 
pemetrexed vs. bevacizumab vs. pemetrexed/bevacizumab) will 
provide further data in that regard.
Different doses of bevacizumab were tested in different set-
tings, and in NSCLC both the higher (15 mg/kg every 3 weeks) 
and lower (7.5 mg/kg every 3 weeks) doses were tested, but direct 
comparison of both dose levels for efficacy was not performed in 
the larger landmark trials. However, the ABIGAIL trial, designed 
as a correlative biomarker finding study of bevacizumab com-
bined to a platinum doublet, randomized patients to receive 7.5 
or 15 mg/kg. Although survival was not the primary endpoint of 
this study and with the caveat of an insufficient patient cohort 
(n = 303) to adequately compare the clinical effect of dose, no 
difference in PFS and OS was observed between both dose levels 
of bevacizumab (27). Considering these data and results from 
the aforementioned meta-analyses suggesting similar clinical 
benefit from bevacizumab at both dose levels, the optimal dose 
of bevacizumab is still debatable (20, 21).
Combination with Tyrosine Kinase Inhibitors
The addition of bevacizumab to erlotinib was initially attempted 
in patients with refractory NSCLC who were unselected for 
activating EGFR mutations, but no improvements in survival 
were obtained with the combination therapy (28). More recently, 
a Japanese phase II study evaluated the same combination of 
erlotinib/bevacizumab in patients with treatment-naïve EGFR-
mutated (exon 19 and 21 alterations) NSCLC (29). The results 
demonstrated a substantial improvement in PFS (16.0 vs. 
9.7 months, HR 0.54, p = 0.0015), but the study was not powered 
to compare OS (29).
These encouraging results have been suggested to be due to 
an increased uptake of erlotinib in tumor cells that is potentiated 
by bevacizumab in addition to the actual blockade of angiogenic 
signaling (30).
The preliminary results of another open label single arm phase 
II trial from Europe, the BELIEF study, yielded provocative results 
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and met its 1-year PFS endpoint for the entire cohort [55.6% 
(95% CI: 44.7–66.6%); median: 13.6 months], including patients 
with T790M-mutated NSCLC [1-year PFS: 60.2% (95% CI: 
45.6–74.8%); median: 15.4 months] (31). Based on these results, 
erlotinib/bevacizumab received approval as first-line treatment 
of patients with EGFR-mutated NSCLC in June 2016 in Europe. 
Another ongoing study, the ACCRU (NCT01532089) trial, has 
completed accrual in the US, and its results will help confirm the 
available data.
TARGeTinG veGF-R
Ramucirumab
This fully human mAb targeting VEGFR-2 first demonstrated 
its efficacy in gastric and colorectal cancers (32–34). The 
development in NSCLC was somewhat more challenging. 
After the initial open label phase II data demonstrated favora-
ble responses, another phase II study randomized patients to 
cisplatin/pemetrexed followed by pemetrexed maintenance 
vs. cisplatin/pemetrexed/ramucirumab followed by ramu-
cirumab-pemetrexed maintenance (35, 36). Unfortunately, the 
latter trial did not meet its primary endpoint (PFS: 7.2 vs. 5.6 
for the ramucirumab arm; p = 0.132) (36). Further develop-
ment of ramucirumab in the first-line setting was subsequently 
halted.
The activity of ramucirumab in NSCLC was nonetheless 
demonstrated in the phase III REVEL trial, where a docetaxel/
ramucirumab combination was compared to docetaxel alone 
in the second-line setting (Table 1) (37). Of note, patients who 
previously received bevacizumab and those who had squamous 
histology were not excluded. Modest but statistically significant 
improvements in OS [10.5 vs. 9.1 months; HR: 0.86 (0.75–0.98); 
p =  0.023] and PFS [4.5 vs. 3.0  months; HR: 0.76 (0.68–0.86); 
p < 0.0001] led to FDA approval in combination with docetaxel 
regardless of histological subtype. However, the use of ramu-
cirumab is not widely adopted since some experts believe that 
the OS improvement, although statistically significant, might not 
be clinically meaningful in accordance with the ASCO definition 
for expensive drugs, particularly if these improvements come at 
the expense of added toxicities (38).
TYROSine KinASe inHiBiTORS  
OF AnGiOGeneSiS
The appeal of antiangiogenic TKIs stemmed from their success in 
renal cell carcinoma as well as from their ease of administration, 
which led to further development in different other cancer types. 
Unfortunately, different TKIs failed to produce consistent success 
in the treatment of advanced NSCLC.
Combining sorafenib with a platinum doublet in the first-line 
setting did not demonstrate any survival benefit (39). Two studies 
evaluating sunitinib combined with erlotinib in the second-line 
setting in patients with wild-type EGFR, or with pemetrexed, also 
failed to demonstrate efficacy of the combination therapies (40, 
41). Combining pazopanib with a platinum doublet resulted in 
excessive toxicities (42).
Among newer multi-kinase inhibitors, the phase II/III study 
evaluating cediranib in addition to frontline carboplatin/pacli-
taxel was halted for futility on the basis of excessive toxicities, 
and the phase III MONET trial testing motesanib, also in com-
bination with frontline carboplatin/paclitaxel, did not result in 
significant OS improvements (43, 44). Another TKI, vandetanib, 
was assessed in four phase III trials, two of which (ZEAL and 
ZODIAC trials) evaluated the agent in combination with doc-
etaxel or pemetrexed maintenance, whereas the other two studies 
tested vandetanib as a single agent in second or subsequent lines 
of therapy, but neither of these studies had a positive impact 
on survival, and the combination therapies mostly resulted in 
increased toxicities (45–48).
nintedanib
The triple angiokinase inhibitor nintedanib is the only TKI 
agent that has shown significant results when tested in the phase 
III LUME-Lung1 study (Table  1). This agent was tested in the 
second-line setting of patients with advanced NSCLC (both 
squamous and non-squamous histologies were included) in 
combination with docetaxel, and the study met its primary PFS 
endpoint in comparison with docetaxel monotherapy (3.4 vs. 
2.7 months; HR, 0.79; 95% CI, 0.68–0.92; p = 0.0019) but failed 
to demonstrate differences in survival for the global population 
(49). When patients were evaluated in a prespecified subgroup 
analysis, the combination therapy showed improvements in OS 
for patients with an adenocarcinoma histology who progressed 
within 9 months of first-line therapy (10.9 vs. 7.9 months; HR, 
0.75; 95% CI, 0.60–0.92; p =  0.0073) and for all patients with 
adenocarcinoma (12.6 vs. 10.3  months; HR, 0.83; 95% CI, 
0.70–0.99; p = 0.0359). A confirmatory phase III trial, the LUME 
Columbus study (NCT02231164), with the same design, but 
excluding patients with squamous histology, was terminated for 
slow accrual. The LUME-Lung 2 study, examining a pemetrexed/
nintedanib combination in the second-line setting, also demon-
strated a modest but significant PFS improvement in comparison 
with pemetrexed monotherapy (PFS: 4.4 vs. 3.6  months; HR, 
0.83, 95% CI, 0.70–0.99; p = 0.0435) but failed to demonstrate 
a survival benefit (Table 1) (50). As such, this agent has received 
approval in Europe for the second-line treatment of NSCLC in 
combination with docetaxel, but FDA approval has not been 
granted.
COMBinATiOnS wiTH iMMUnOTHeRAPY
The demonstration of durable responses in patients with advanced 
NSCLC, through the use of ICIs, has led to considerable enthusi-
asm within the scientific community. The first anti-programmed 
death-1 (PD-1) agents, nivolumab and pembrolizumab, gained 
accelerated approval for the treatment of metastatic NSCLC in 
the second-line setting after demonstrating significant clinical 
activity in this context (51–53). Additionally, agents targeting 
programmed death-ligand 1 (PD-L1)—such as atezolizumab, 
durvalumab, and avelumab—are also in advanced stages of 
development, and some have gained approval in several other 
indications (54–56). Most recently, pembrolizumab was also 
found to be superior to standard platinum-based chemotherapy 
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and gained approval for the first-line treatment of metastatic 
NSCLC with positive PD-L1 expression—defined as tumor pro-
portion score of 50% or more (57). Despite their efficacy, reported 
overall RRs are less than optimal (20–25% in the second-line and 
45% in the frontline setting for selected patients), which gives 
rise to different strategies aimed at improving responses to ICIs. 
Therefore, investigators are attempting combinations of ICIs 
with chemotherapy, radiation therapy, cancer vaccines, oncolytic 
viruses, and targeted therapies in order to overcome resistance 
mechanisms (58). Some evidence suggests that angiogenesis 
might be associated with immunosuppression within the tumor 
microenvironment thereby potentiating immune-escape of 
tumor cells (59).
The complex relationship between VEGF and tumor-related 
immune regulation involves several key pathways that lead to 
an immunosuppressive microenvironment. VEGF is effectively 
capable of inducing inhibitory immune cells such as T-regulatory 
cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (60, 
61). Additionally, exposure to VEGF at pathologic levels might 
inhibit the differentiation and/or emigration T-cell progenitors 
from the thymus resulting in a state of systemic cancer-related 
immunosuppression (62). Moreover, it seems that lymphocyte 
influx across the vascular endothelium toward the tumor is 
affected by VEGF, which leads to a defect in intercellular adhesion 
molecule-1 and vascular cell adhesion molecule-1 clustering at 
the endothelial cell surface through nitric oxide production and 
subsequently leads to defective lymphocyte adhesion and migra-
tion toward the tumor environment (63).
On the other hand, preclinical models have shown that the use 
of antiangiogenic agents such a sunitinib or cabozantinib lead to 
an increase in CD4+ and CD8+ T-cells infiltration and reduce 
PD-1 expression within these cells while the influx of MDSCs and 
Tregs toward tumor tissue seems to be decreased (64–66).
In light of these findings, multiple trials are currently inves-
tigating combinations of immunotherapy and antiangiogenic 
drugs in different types of cancer. The most encouraging results 
in this context come from the experience with melanoma, where 
immunotherapy achieved its first successes. Promising phase I 
data indicated that a combination of ipilimumab and bevacizumab 
is both safe and effective with a median OS of 25.1 months and a 
disease control rate of 67.4%, thereby supporting the preclinical 
rationale of VEGF impact on immune regulation (67).
In NSCLC, preliminary data from a phase I study evaluating a 
nivolumab/bevacizumab combination vs. nivolumab monother-
apy as maintenance after initial platinum-based chemotherapy 
suggested a favorable adverse-events profile for both arms (68). 
This study is certainly not powered to provide information in 
regards to optimal regimens, but the results indicated median 
PFS values with combination therapy that compared favorably 
to those obtained with the comparator arm (PFS: 37.1  weeks 
for nivolumab/bevacizumab, whereas nivolumab monotherapy 
yielded 16 and 21.4 weeks of PFS in patients with squamous and 
non-squamous histology, respectively) (68).
Another phase Ia/dose-limiting toxicity evaluation explored 
the addition of ramucirumab to pembrolizumab in patients with 
advanced NSCLC, gastric-esophageal cancers, and urothelial 
carcinoma (69). Preliminary data also indicate the safety of 
this combination as no dose-limiting toxicities were identi-
fied in patients with NSCLC (only one patient with urothelial 
carcinoma experienced severe toxicities requiring treatment 
discontinuation).
These encouraging safety data will certainly need to be 
cemented with efficacy data from larger trials exploring ICIs/
antiangiogenesis combinations before any definitive conclusions 
can be drawn. Several challenges involving optimal dosing and 
treatment schedules remain to be resolved before such combina-
tions can be considered for clinical practice especially since several 
combinations involving immunotherapy (with chemotherapy, 
radiation therapy, vaccines, etc.) are being tested and could have 
better efficacy when tested in larger trials.
COnCLUSiOn
Identifying the VEGF pathway as a key regulator in angiogenesis 
and in subsequent tumor growth and metastasis has led to the 
development of several agents targeting the pathway’s different 
components. Bevacizumab appears to be the most successful 
antiangiogenic, but ramucirumab and nintedanib have also dem-
onstrated clinical efficacy in the second-line setting. Although 
some experts believe that the benefits of these agents have pla-
teaued, the promising results of an erlotinib/bevacizumab combi-
nation in EGFR-mutated lung cancer have proven otherwise. The 
intricate relationship between immunosuppression and angio-
genesis indicates that a synergistic relationship could result from 
a combination of ICIs and angiogenesis inhibitors with relatively 
favorable toxicity profiles and has sparked a renewed interest in 
the study of antiangiogenic drugs. However, our comprehension 
of cancer-related immune modulation barely scratches at the 
surface of a vast compendium of knowledge. Many challenges 
need to be addressed before optimal combination therapies are 
defined.
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